ATR and non-small cell lung carcinoma: The ATM inhibitor (ATMi; KU-60019) and ATR inhibitor (ATRi; AZD6738) potently inhibit their target and effectively sensitised glioma cells (ATMi) and NSCLC cells (ATRi) to radiation and were used at doses with confirmed target inhibition18,19.